Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Immunology to the people

Tue, 15th Sep 2020 13:21

* European shares rise, STOXX 600 +0.8%

* Banking shares fall ahead of U.S., UK central bank meetings

* H&M on track for best day in nearly 6 months

* Peugeot maker and Fiat Chrysler restructure terms of their planned merger
Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Danilo Masoni
(danilo.masoni@thomsonreuters.com) and Stefano Rebaudo (stefano.rebaudo@thomsonreuters.com) in
Milan.

IMMUNOLOGY TO THE PEOPLE (1221 GMT)

It may sound obvious but COVID-19 is indeed going to give a nice shot in the arm to the
global vaccines market.

Jefferies has looked into it and sees the business surging above $50 billion by 2025 from
$36 billion currently.

"COVID-19 has introduced immunology to the masses & heightened infectious disease awareness,
with governments also reassessing preparedness & health economics of prevention. We see this
kick-starting a new era for vaccines," they say.

(Danilo Masoni)

*****

STILL LOVE FOR UK COMPANIES (1155 GMT)

As the UK and the EU seem far from reaching a Brexit deal to shape their relationships after
a transition period ends in December, one would think it would be best to keep distance from
British equities, which has lagged global stocks.

Well, UBS disagrees saying it likes the UK equity market for its "attractive valuation" at
15.4x 12-month trailing P/E, which is a 30% discount to MSCI All-Country World.

The Swiss bank is also confident there is plenty of time to reach a Brexit deal.

"We think that the political and economic incentives point to an agreement eventually being
reached" it says in its House View note.

Then, it sees a strong bounce back next year.

"We expect earnings growth to fall substantially this year, but by 2021 we anticipate a
robust rebound driven by an economic bounce-back and a recovery in the oil price".

(Joice Alves)

*****

SO MUCH FOR TINA! EM RETURNS ALIVE AND KICKING (1135 GMT)

The extent of the demise of real returns in developed world bond markets is a hotly-debated
topic which has pretty much fed the TINA (there is no alternative to stocks) narrative for the
last few years.

But looking beyond developed markets, real returns are very much alive in emerging market.

JP Morgan's Government Bond Index Emerging Markets Global Diversified, which tracks emerging
local currency debt, is up around 2.8% during the quarter to date, compared to 0.1% for one to
three year U.S. Treasury bonds.

South Africa, Turkey, Indonesia and Brazil offer the highest cushion in real carry, as
measured by nominal local government bond yields adjusted for 1-year-ahead inflation
expectations compared to U.S. dollar 3-month Libor, HSBC said in a research note.

Risk-adjusted real carry is most favourable for Indonesia, South Africa and Russia, the bank
noted.

"The Brazil curve is the second-steepest EM high-yielding curve, but this analysis suggests
that there is little compensation for extending along the curve," André de Silva, HSBC's head of
global EM rates research, wrote in the note.

"We prefer having exposure to Russia (buy 5yr OFZs) and Indonesia (i.e. buy 5yr IndoGBs)
rather than South Africa or Brazil."

Carry after being risk-adjusted relegates Turkey to being among the emerging market
high-yielders providing the least cushion, the bank said, outlying concerns about the recent
acceleration in FX depreciation and backdoor policy tightening.

India was the least favourable on a risk-adjusted basis, the bank added. HSBC advised
positioning for higher rates in India and a steeper curve, as well as an easing in the potency
of the bond buying via the central bank's auctions.

(Tom Arnold)

*****

VALUE IS A EUROPE THING (1041 GMT)

Though it has not been working much lately, more analysts are still advocating a call for
value, but mostly in value-heavy Europe.

The value/growth rate has been essentially flat since April while it has staged a small
resurgence recently with value outperforming growth by around 3% since September 2, according to
Credit Suisse data.

Here are the reasons to believe that it is value time: It tends to follow PMIs with a
three-month lag; the euro seems to be under control with the ECB worried about its
strengthening; the price to book of value relative to growth in Europe is now two standard
deviations below its average, a Credit Suisse analyst note says.

“We believe that in Europe, the absence of megacap tech will allow European value to
outperform, and thus we remain overweight,” it adds.

While “we see scope for the equity risk premium to decline, underpinning the attractions of
the big cap tech.”

Credit Suisse highlights Brenntag, Siemens and Smiths Group,
while shares in CRH, Lafarge, Enel, Smurfit Kappa RWE
appear cheap.

(Stefano Rebaudo)

*****

WHAT’S IN A CORPORATE EARNINGS DATE? (1007 GMT)

Plenty, if data analytics firm Raven Pack is to be believed.

Advances or delays in earnings announcement dates can be predictive of positive or negative
results and investment strategies based on such date changes can deliver sizeable returns,
according to Peter Hafez, chief data scientist at Raven Pack.

Investors have long used traditional fundamental methods to forecast company earnings.
Intensifying competition and the alternative data explosion over the past decade have led to
rapid adoption of novel approaches in forecasting stock performance.

Company executives often use strategic timing to distribute earnings results. Some studies
have shown that earnings delays may signal weak performance, while advancing the date may be a
sign of good news.

Using earnings calendar change records for over 8,000 stocks globally since 2006 with a
central focus on the U.S. stock market, data scientists at the firm found portfolio investment
strategies that bought after advances, and sold after delays, produced annual excess returns of
8.4%, for portfolios of mid to large-cap stocks and 18.6% for small-caps.

However, mid-to large cap companies are more prone to deeper losses for earnings date delays
while small cap gains are more amplified for earning dates advances. Typically, the
outperformance ebbs quickly within a few days, the study found. For a link to the study, see https://www.ravenpack.com/research/trading-earnings-calendar/

(Saikat Chatterjee)

*****

NOT ALL MERGERS FALL APART (0928 GMT)

Let's face it: completing merger deals has become more challenging in this new COVID-19
world.

Take LVMH/Tiffany in luxury and Fiat Chrysler/PSA in the automotive sector. Both deals were
bigly challenged by the turmoil created by the pandemic but while LVMH resolved to call off the
deal (with political interference playing crucial part in the decision), the merger to create
the world's No. 4 carmaker is nevertheless going ahead.

But that comes with a cost, which seems investors are willing to pay, and may raise further
hopes that M&A could recover after activity collapsed in the second quarter of 2020.

To preserve cash, FCA will nearly halved its pre-merger special dividend to 2.9 billion
euros and France's PSA will in turn postpone the planned spinoff of its 46% stake in parts maker
Faurecia until after the merger's closing.

The decision might have been a tough one to take but after all that will result in a
financially stronger group, which combined with sharp increase in the synergy target explains
why their shares reacted positively at the start of trading.

It looks that investors are looking beyond any short term gains, preferring synergies
tomorrow than dividends today.

"The higher value of the industrial synergies more than offset any revision of terms," says
Equita.

PSA shares hit a 6-month high before retreating to trade down 1% on the day, while FCA
shares are up 6%.

(Danilo Masoni)

*****

STOCK PRICES RANGEBOUND UP TO END 2020 (0910 GMT)

It won’t be all about virus trajectories and macro data for the stock market as there is a
lot going on, starting with the U.S. presidential elections.

After UBS yesterday said the stock market is fragile but it was confident that investors
will turn their focus on the positives soon, JP Morgan analysts sound even more cautious.

They line up risks that equities will face and say that the STOXX 600 index will remain
rangebound by end 2020.

This is in line with our Aug 26 poll which showed investors were on average expecting the
STOXX 600, currently at 370 points, to end the year at 375 points.

On the U.S, presidential election front, the real danger is the vote ending along the lines
of the Bush versus Gore Florida recount in 2000, leading to a ”legislative paralysis for some
time,” a JP Morgan research note says.

Foreign trade is going to be an issue whoever wins as “polls suggest that the unfavourable
views of China have become firmly bipartisan,” it adds.

Technicals are not helping as positioning is far from depressed, with “short interest and
put/call ratios at lows.”

Besides, fundamentals could soften if labour market improvement stalls and if the virus
dampens the recovery; default rates might spike; geopolitical risks are in place with “Brexit,
Russia, Iran and other.”

“We do not think that any of the above risks should necessarily be seen as a clear base
case, but the potential is that some of them might be realized.”

(Stefano Rebaudo)

*****

OPENING SNAPSHOT: BIG MOVES UNDER THE FLAT SURFACE (0715 GMT)

European shares are off to a cautious start but under the flat surface there are some big
moves.

H&M is rallying 10% after its Q3 profit beat expectations, while in the auto sector
FCA is up 7% and PSA is gaining 1% after they revised the terms of their
merged in a bid to conserve cash. The revision meant that PSA will postpone the sale of its
stake in parts maker Faurecia, which is down 8.6%.

Strong retail sales are pushing online supermarket Ocado up 4.7%.

After initial gains at the open, the STOXX 600 has now pulled back, trading down
0.10%.

(Danilo Masoni)

*****

PSA/FCA, PAYMENTS DEALS, BANKS AND VACCINE NEWS ON OUR RADAR (0639 GMT)

While rangebound trading looks set to continue in typical pre-Fed fashion -- EUROSTOXX 50
futures are just flat -- on the corporate front some dealmaking headlines could liven up the
session, along with fresh vaccine updates.

PSA and Fiat Chrysler (FCA) have revised the terms of their planned
merger to conserve cash. FCA will cut to 2.9 billion euros the cash portion of a 5.5 billion
euro special dividend, while the French group will postpone to after the merger's closing the
planned spinoff of its 46% stake in parts maker Faurecia.

In the buoyant payments industry, Klarna Bank AB has raised $650 million at a valuation of
$10.65 billion from investors led by Silver Lake, while in Italy la Repubblica
reports that Nexi and smaller rival SIA are nearing a preliminary agreement for a
merger

In banks, one day after talk of a potential tie-up between Credit Suisse and UBS
, the focus may turn to Spain. A source said Caixabank is
considering a bid for Bankia that could value it at around 4 billion euros -- a
premium of between 15% and just above 20% over Bankia's average 3-month share price.

Vaccine news does not seem so bright today with sources saying AstraZeneca's
COVID-19 vaccine trial remains on hold in the United States pending a U.S. investigation into a
serious side effect in Britain even as other trials of the vaccine resume.

Shares in Zurich-lised Siegfried however rose 1.9% in premarket after a contract
with BioNTech to fill and pack a potential COVID-19 vaccine, while Lonza also gained
after unveiling a collaboration deal to expand the manufacturing of Humanigen's COVID-19
therapeutic candidate Lenzilumab.

Meantime in the UK, the pandemic generated huge demand for online deliveries, sending UK
online supermarket Ocado's retail sales in the 13 weeks to Aug. up 52%.

We'll also keep an eye on Daimler after courts documents showed it will pay $2.2
billion violating U.S. clean air laws and to resolve claims from 250,000 U.S. vehicle owners.

(Danilo Masoni)

*****

MORNING CALL: A CHOPPY DAY AHEAD? (0530 GMT)

European bourses look set for another choppy session today with futures moving between flat
and slightly lower, while spreabetters' calls are pointing to marginal gains.

The main event of this week is the Fed's two-day policy meeting which could help provide
fresh direction, while the German ZEW may draw some attention later today.

The day in Asia saw Chinese stocks rise following data that showed industrial output
expanded for a fifth straight month in August, while the Nikkei pulled back.

Meantime, U.S. futures rose slightly.

Futures for the S&P 500 were up 0.3%, while EUROSTOXX 50 futures eased 0.2%

(Danilo Masoni)

*****

More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.